Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

• Conditions: Breast Cancer; Bevacizumab; Neoadjuvant Chemotherapy; Molecular Targeted Therapy
• Interventions: Drug: bevacizumab

• Registration Number: NCT01652560
• Lead Sponsor: LiNanlin,Ph.D, Chief Physician,Clinical Professor

Brief Summary

- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06
• Status Verified: 2012-07
• Study First Submitted: 2012-07-21
• Study First Submitted QC: 2012-07-25
• Last Update Submitted: 2012-07-25
• Study First Posted: 2012-07-30
• Last Update Posted: 2012-07-30
• Primary Completion: 2014-06
• Study Completion: 2014-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• HER2-negative breast cancer patients
• Without surgery
• Plans to neoadjuvant chemotherapy

Read More

Exclusion Criteria

• HER2-positive breast cancer patients
• Post-operative patients

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
bevacizumab combined neoadjuvant chemotherapy	bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Objective Response Rate	From enrollment to disease progression	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

Secondary Outcome Measures

Name	Time	Method
overall response	From enrollment to disease progression	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

Trial Locations

Locations (1)

Xijing Hospital ， Fourth Military Medical University; 🇨🇳 Xi'an, Shaanxi, China